Sino Biopharm spends HK$10.05 million to buy back 1.80 million shares on 23 April

Bulletin Express04-23 17:08

Sino Biopharmaceutical Limited (SBP Group) reported to the Hong Kong Stock Exchange that it repurchased 1.80 million ordinary shares on-market on 23 April 2026. The shares were bought at prices between HK$5.58 and HK$5.60, for a total consideration of HK$10.05 million, and are earmarked for cancellation.

Including the 1.73 million shares bought on 21 April and the 1.72 million shares bought on 22 April, the company has repurchased 5.25 million shares this week at a combined cost of approximately HK$30.15 million. These repurchases represent about 0.03 % of the company’s 18.75 billion issued shares outstanding before the transactions.

Under the general mandate granted on 10 June 2025, Sino Biopharm is authorised to repurchase up to 1.88 billion shares. Cumulative buybacks executed under this mandate have reached 20.60 million shares, equivalent to 0.11 % of the company’s issued share capital on the mandate date.

Following the latest transactions, the company’s issued share capital remains unchanged at 18.75 billion shares, as the repurchased shares have not yet been cancelled. A 30-day moratorium on new share issues or treasury share sales is in effect until 23 May 2026, in line with Hong Kong listing regulations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1192264851?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-23 17:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192264851","market":"us","top_or_hot":-1,"title":"Sino Biopharm spends HK$10.05 million to buy back 1.80 million shares on 23 April","media":"Bulletin Express","content":"<p>Sino Biopharmaceutical Limited (SBP Group) reported to the Hong Kong Stock Exchange that it repurchased 1.80 million ordinary shares on-market on 23 April 2026. The shares were bought at prices between HK$5.58 and HK$5.60, for a total consideration of HK$10.05 million, and are earmarked for cancellation.</p>\n<p>Including the 1.73 million shares bought on 21 April and the 1.72 million shares bought on 22 April, the company has repurchased 5.25 million shares this week at a combined cost of approximately HK$30.15 million. These repurchases represent about 0.03 % of the company’s 18.75 billion issued shares outstanding before the transactions.</p>\n<p>Under the general mandate granted on 10 June 2025, Sino Biopharm is authorised to repurchase up to 1.88 billion shares. Cumulative buybacks executed under this mandate have reached 20.60 million shares, equivalent to 0.11 % of the company’s issued share capital on the mandate date.</p>\n<p>Following the latest transactions, the company’s issued share capital remains unchanged at 18.75 billion shares, as the repurchased shares have not yet been cancelled. A 30-day moratorium on new share issues or treasury share sales is in effect until 23 May 2026, in line with Hong Kong listing regulations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sino Biopharm spends HK$10.05 million to buy back 1.80 million shares on 23 April</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSino Biopharm spends HK$10.05 million to buy back 1.80 million shares on 23 April\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-23 17:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sino Biopharmaceutical Limited (SBP Group) reported to the Hong Kong Stock Exchange that it repurchased 1.80 million ordinary shares on-market on 23 April 2026. The shares were bought at prices between HK$5.58 and HK$5.60, for a total consideration of HK$10.05 million, and are earmarked for cancellation.</p>\n<p>Including the 1.73 million shares bought on 21 April and the 1.72 million shares bought on 22 April, the company has repurchased 5.25 million shares this week at a combined cost of approximately HK$30.15 million. These repurchases represent about 0.03 % of the company’s 18.75 billion issued shares outstanding before the transactions.</p>\n<p>Under the general mandate granted on 10 June 2025, Sino Biopharm is authorised to repurchase up to 1.88 billion shares. Cumulative buybacks executed under this mandate have reached 20.60 million shares, equivalent to 0.11 % of the company’s issued share capital on the mandate date.</p>\n<p>Following the latest transactions, the company’s issued share capital remains unchanged at 18.75 billion shares, as the repurchased shares have not yet been cancelled. A 30-day moratorium on new share issues or treasury share sales is in effect until 23 May 2026, in line with Hong Kong listing regulations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中国生物制药","start_time":0,"source_url":"","article_id":"1192264851","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192264851","pubTimestamp":1776935325,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Sino Biopharmaceutical Limited (SBP Group) reported to the Hong Kong Stock Exchange that it repurchased 1.80 million ordinary shares on-market on 23 April 2026. The shares were bought at prices...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01177":"中国生物制药"},"translate_title":"中国生物制药4月23日斥资1005万港元回购180万股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"Sino Biopharmaceutical Limited (SBP Group) reported to the Hong Kong Stock Exchange that it repurchased 1.80 million ordinary shares on-market on 23 April 2026. The shares were bought at prices between HK$5.58 and HK$5.60, for a total consideration of HK$10.05 million, and are earmarked for cancellation.\nIncluding the 1.73 million shares bought on 21 April and the 1.72 million shares bought on 22 April, the company has repurchased 5.25 million shares this week at a combined cost of approximately HK$30.15 million. These repurchases represent about 0.03 % of the company’s 18.75 billion issued shares outstanding before the transactions.\nUnder the general mandate granted on 10 June 2025, Sino Biopharm is authorised to repurchase up to 1.88 billion shares. Cumulative buybacks executed under this mandate have reached 20.60 million shares, equivalent to 0.11 % of the company’s issued share capital on the mandate date.\nFollowing the latest transactions, the company’s issued share capital remains unchanged at 18.75 billion shares, as the repurchased shares have not yet been cancelled. A 30-day moratorium on new share issues or treasury share sales is in effect until 23 May 2026, in line with Hong Kong listing regulations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1192264851","isCrawlerRequest":true}